⚡

Metabolic & Endocrine

104 drugs in pipeline from 10 companies

104

Drugs in Pipeline

Companies

Upcoming Catalysts

Phase 3 Trials

Upcoming Catalysts

Dec 2025~

RYTM⭐Phase 3Phase 2

Setmelanotide Phase 3 Results Expected

Setmelanotide • Genetic Obesity

Dec 2025~

RYTM⭐Phase 3Phase 3

Placebo Phase 3 Results Expected

Placebo • Obesity

Jan 31

RYTMPhase 2Phase 2

LB54640 Phase 2 Results Expected

LB54640 • Hypothalamic Obesity

Mar 2026~

MDGL⭐Phase 3Phase 3

Resmetirom Phase 3 Results Expected

Resmetirom • NASH

Apr 2026~

AKRO⭐Phase 3Phase 3

Placebo Phase 3 Results Expected

Placebo • NASH/MASH

Apr 2026~

AKRO⭐Phase 3Phase 2

Efruxifermin Phase 3 Results Expected

Efruxifermin • NASH - Nonalcoholic Steatohepatitis

Apr 2026~

LLY⭐Phase 3Phase 3

Retatrutide Phase 3 Results Expected

Retatrutide • Obesity

View all catalysts

Pipeline by Phase

Phase 3

Phase 2

Active Companies

OPKO HEALTH, INC.

Sanofi

Novo Nordisk A/S

Esperion Therapeutics, Inc.

Astellas Pharma Inc.

Eli Lilly and Company

16 drugs

RYTM

RHYTHM PHARMACEUTICALS, INC.

3 drugs

4151.T

Kyowa Kirin Co., Ltd.

Ascendis Pharma A/S

89bio, Inc.

Related Conditions

diabetesobesitymetabolicthyroidhormoneendocrineinsulinglucosehba1cweight lossglp-1nafldnashfatty liverhyperlipidemiadyslipidemiaosteoporosis